948,184 Shares in 4D Molecular Therapeutics, Inc. $FDMT Bought by Parkman Healthcare Partners LLC

Parkman Healthcare Partners LLC purchased a new position in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) in the second quarter, Holdings Channel.com reports. The firm purchased 948,184 shares of the company’s stock, valued at approximately $12,611,000.

A number of other institutional investors and hedge funds have also bought and sold shares of FDMT. Persistent Asset Partners Ltd bought a new position in shares of 4D Molecular Therapeutics in the second quarter worth about $1,936,000. Exome Asset Management LLC purchased a new stake in shares of 4D Molecular Therapeutics during the first quarter worth about $1,216,000. Dimensional Fund Advisors LP raised its stake in 4D Molecular Therapeutics by 77.3% during the 1st quarter. Dimensional Fund Advisors LP now owns 522,823 shares of the company’s stock valued at $4,863,000 after purchasing an additional 227,982 shares during the period. Deutsche Bank AG bought a new stake in 4D Molecular Therapeutics during the 2nd quarter valued at approximately $9,456,000. Finally, Perigon Wealth Management LLC purchased a new position in 4D Molecular Therapeutics in the 2nd quarter worth approximately $1,944,000. 99.27% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several research analysts have weighed in on FDMT shares. The Goldman Sachs Group restated a “buy” rating and issued a $32.00 price target on shares of 4D Molecular Therapeutics in a research note on Thursday, August 13th. Chardan Capital raised shares of 4D Molecular Therapeutics to a “strong-buy” rating in a report on Tuesday, July 28th. Weiss Ratings restated a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a research report on Friday, July 17th. HC Wainwright restated a “buy” rating and set a $36.00 target price on shares of 4D Molecular Therapeutics in a research report on Monday, July 20th. Finally, Wall Street Zen cut shares of 4D Molecular Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, 4D Molecular Therapeutics has an average rating of “Moderate Buy” and an average price target of $29.62.

Insiders Place Their Bets

In related news, insider Scott Bizily sold 9,810 shares of the company’s stock in a transaction on Tuesday, June 23rd. The shares were sold at an average price of $12.00, for a total transaction of $117,720.00. Following the sale, the insider owned 8,617 shares of the company’s stock, valued at $103,404. This represents a 53.24% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider David Kirn sold 12,415 shares of 4D Molecular Therapeutics stock in a transaction on Monday, August 3rd. The stock was sold at an average price of $10.05, for a total transaction of $124,770.75. Following the completion of the transaction, the insider directly owned 871,737 shares of the company’s stock, valued at $8,760,956.85. The trade was a 1.40% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 200,496 shares of company stock worth $2,240,244. 7.90% of the stock is owned by insiders.

4D Molecular Therapeutics Stock Performance

NASDAQ:FDMT opened at $15.39 on Tuesday. The company has a market cap of $850.14 million, a price-to-earnings ratio of -5.85 and a beta of 2.73. 4D Molecular Therapeutics, Inc. has a 1 year low of $5.97 and a 1 year high of $16.93. The stock’s 50 day simple moving average is $11.74 and its two-hundred day simple moving average is $10.17. The company has a debt-to-equity ratio of 0.05, a current ratio of 8.03 and a quick ratio of 8.03.

4D Molecular Therapeutics (NASDAQ:FDMT) last posted its earnings results on Thursday, August 13th. The company reported ($1.04) EPS for the quarter, missing analysts’ consensus estimates of ($1.02) by ($0.02). 4D Molecular Therapeutics had a negative net margin of 194.74% and a negative return on equity of 41.33%. The firm had revenue of $3.78 million for the quarter, compared to the consensus estimate of $3.62 million. As a group, equities analysts anticipate that 4D Molecular Therapeutics, Inc. will post -4.09 earnings per share for the current fiscal year.

4D Molecular Therapeutics Profile

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.